2026-06-29T02:52:17Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1071492025-03-18T15:36:07Zcom_20.500.14352_14col_20.500.14352_15

Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity Cafini, Fabio Aguilar, Lorenzo Alou Cervera, Luis Giménez, María José Sevillano Fernández, David Torrico, Martha González Hidalgo, Natalia Granizo, Juan José Martín Herrero, José Emilio Prieto Prieto, José 611.02 Ceftriaxone Cefotaxime Cefixime Cefpodoxime Initial Inoculum Microbiología médica 2414 Microbiología This study explores the killing kinetics within 12 h of four oral third-generation cephalosporins against ten Streptococcus pneumoniae strains exhibiting cefotaxime minimum inhibitory concentrations (MICs) from 0.03 to 2 microg/ml. Killing curves were performed with concentrations achievable in serum after standard doses (0.015-4 microg/ml). Reductions of 90% were achieved with all compounds at serum-achievable concentrations for strains exhibiting cefotaxime MIC < or = 0.5 microg/ml. Against strains with cefotaxime MIC > or = 1 microg/ml, only cefditoren reached a 90% reduction with concentrations of 0.5-1 microg/ml doses. At 4 microg/ml, cefditoren and cefotaxime reached 99.9% reduction in seven of the ten strains studied. At serum-achievable concentrations, cefdinir and cefixime were not bactericidal against strains exhibiting cefotaxime MIC > or = 0.25 microg/ml and > or = 0.5 microg/ml, respectively. Cefditoren showed the best killing kinetic profiles and this observation may be important when choosing an oral third-generation cephalosporin as initial or sequential therapy GlaxoSmithKline S.A. Depto. de Medicina Fac. de Medicina TRUE pub 2024-07-29T08:31:50Z 2024-07-29T08:31:50Z 2008-02-26 journal article VoR https://hdl.handle.net/20.500.14352/107149 0934-9723 10.1007/s10096-008-0493-7 1435-4373 eng Cafini F, Aguilar L, Alou L, Giménez MJ, Sevillano D, Torrico M, González N, Granizo JJ, Martín-Herrero JE, Prieto J. Cidal activity of oral third-generation cephalosporins against Streptococcus pneumoniae in relation to cefotaxime intrinsic activity. Eur J Clin Microbiol Infect Dis. 2008 Aug;27(8):679-83. restricted access application/pdf Springer